CriticalNatural opium alkaloids×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B)
Updated · Methodology
Mechanism
Phenelzine is a potent inhibitor of the enzyme monoamine oxidase (MAO), so it belongs to the MAO inhibitors (phenelzine label, US Food and Drug Administration, FDA). According to the US morphine label, MAO inhibitors may potentiate the effects of morphine, including respiratory depression, coma and confusion (FDA morphine label, section 5.8). The same label states that MAO inhibitor interactions with opioids may present as serotonin syndrome or opioid toxicity (FDA morphine label, section 7). Phenelzine is not authorised in Spain; its only official documents are from the US.
Symptoms
The documents do not say how this particular combination presents: they contraindicate it pre-emptively. The US morphine label warns of respiratory depression, confusion and coma (morphine label, US Food and Drug Administration, FDA, section 5.8) or serotonin syndrome (FDA morphine label, section 7). Respiratory depression is most likely when morphine is started or the dose is increased, and if it is not recognised and treated at once, it may lead to respiratory arrest and death (FDA morphine label, section 5.2).
Management
The combination is contraindicated. Spanish summaries of product characteristics (SmPCs) for oral morphine contraindicate morphine with monoamine oxidase (MAO) inhibitors and within two weeks of stopping them (morphine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.3), and phenelzine is an MAO inhibitor according to its own label (phenelzine label, US Food and Drug Administration, FDA). The US morphine label sets the same 14-day ban and names phenelzine among the examples (FDA morphine label, sections 4 and 7). Start morphine no earlier than two weeks after stopping phenelzine (morphine SmPC, AEMPS, section 4.3; FDA morphine label, sections 4 and 5.8), and do not start an MAO inhibitor while the patient is taking morphine (FDA morphine label, section 17). The Spanish SmPC for injectable morphine is milder: it advises using MAO inhibitors with morphine with caution and at a reduced dose (injectable morphine SmPC, AEMPS, section 4.5). The US phenelzine label prohibits combining phenelzine with central nervous system depressants, including certain narcotic analgesics, but does not name morphine (FDA phenelzine label, Contraindications). Before elective surgery, stop phenelzine at least 10 days in advance (FDA phenelzine label, Warnings).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Nardil (phenelzine sulfate tablets, USP) – prescribing information (2025)– FDA label, Parke-Davis Div of Pfizer, DailyMed setid 513a41d0-37d4-4355-8a6d-a2c643bce6fa, version 11, 06/2025, INDICATIONS AND USAGE, CONTRAINDICATIONS, PRECAUTIONS: Drug Interactions
- AEMPS: Ficha técnica: Morfina Serra 10 mg/ml solución inyectable (nº registro 37473), secciones 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 37473, revisión 09/2026, secciones 4.4 y 4.5
- FDA: MS Contin (morphine sulfate) prescribing information (2026)– FDA, DailyMed setid c354b3bf-86c0-4bb8-8b1f-be2164942698 (Rhodes Pharmaceuticals), version 18, revised 08/2026, Boxed Warning, sections 4, 5.3, 5.8 and 7
- AEMPS: Ficha técnica: Morfina, MST Continus 10 mg (nº registro 57898) (2025)– AEMPS, CIMA, nº registro 57898 (MST Continus 10 mg comprimidos de liberación prolongada), revisión 03/2025, secciones 4.3, 4.4 y 4.5